296 related articles for article (PubMed ID: 26462561)
1. The roles of stem cell memory T cells in hematological malignancies.
Xu L; Zhang Y; Luo G; Li Y
J Hematol Oncol; 2015 Oct; 8():113. PubMed ID: 26462561
[TBL] [Abstract][Full Text] [Related]
2. Role of memory T cell subsets for adoptive immunotherapy.
Busch DH; Fräßle SP; Sommermeyer D; Buchholz VR; Riddell SR
Semin Immunol; 2016 Feb; 28(1):28-34. PubMed ID: 26976826
[TBL] [Abstract][Full Text] [Related]
3. T-memory cells against cancer: Remembering the enemy.
Sarkar I; Pati S; Dutta A; Basak U; Sa G
Cell Immunol; 2019 Apr; 338():27-31. PubMed ID: 30928016
[TBL] [Abstract][Full Text] [Related]
4. Adoptive therapy with CAR redirected T cells for hematological malignancies.
Li S; Yang Z; Shen J; Shan J; Qian C
Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
[TBL] [Abstract][Full Text] [Related]
5. Evolution of peripheral blood T lymphocyte subsets after allogenic or autologous hematopoietic stem cell transplantation.
Puissant-Lubrano B; Huynh A; Attal M; Blancher A
Immunobiology; 2014 Aug; 219(8):611-8. PubMed ID: 24721705
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-specific T-cell Subsets in Human Peripheral Blood and After IFN-γ Immunomagnetic Selection.
Qian C; Wang Y; Cai H; Laroye C; De Carvalho Bittencourt M; Clement L; Stoltz JF; Decot V; Reppel L; Bensoussan D
J Immunother; 2016 Jan; 39(1):27-35. PubMed ID: 26641259
[TBL] [Abstract][Full Text] [Related]
7. Specific Adoptive Cellular Immunotherapy in Allogeneic Stem Cell Transplantation.
Audehm S; Krackhardt AM
Oncol Res Treat; 2017; 40(11):691-696. PubMed ID: 29069663
[TBL] [Abstract][Full Text] [Related]
8. Curtailed T-cell activation curbs effector differentiation and generates CD8
Zanon V; Pilipow K; Scamardella E; De Paoli F; De Simone G; Price DA; Martinez Usatorre A; Romero P; Mavilio D; Roberto A; Lugli E
Eur J Immunol; 2017 Sep; 47(9):1468-1476. PubMed ID: 28671275
[TBL] [Abstract][Full Text] [Related]
9. Generation and application of human induced-stem cell memory T cells for adoptive immunotherapy.
Kondo T; Imura Y; Chikuma S; Hibino S; Omata-Mise S; Ando M; Akanuma T; Iizuka M; Sakai R; Morita R; Yoshimura A
Cancer Sci; 2018 Jul; 109(7):2130-2140. PubMed ID: 29790621
[TBL] [Abstract][Full Text] [Related]
10. Adoptive Immunotherapies After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies.
Xiong Y; Bensoussan D; Decot V
Transfus Med Rev; 2015 Oct; 29(4):259-67. PubMed ID: 26282736
[TBL] [Abstract][Full Text] [Related]
11. T cell therapies following hematopoietic stem cell transplantation: surely there must be a better way than DLI?
Kennedy-Nasser AA; Bollard CM
Bone Marrow Transplant; 2007 Jul; 40(2):93-104. PubMed ID: 17502898
[TBL] [Abstract][Full Text] [Related]
12. Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies.
Tanaka J; Miller JS
Blood Rev; 2020 Nov; 44():100678. PubMed ID: 32229065
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of hematological malignancies with dendritic cells.
Falkenburg JH
Hematol J; 2004; 5 Suppl 3():S96-9. PubMed ID: 15190287
[No Abstract] [Full Text] [Related]
14. Long-term immune reconstitution and infection burden after mismatched hematopoietic stem cell transplantation.
Servais S; Lengline E; Porcher R; Carmagnat M; Peffault de Latour R; Robin M; Sicre de Fontebrune F; Clave E; Maki G; Granier C; Xhaard A; Dhedin N; Molina JM; Toubert A; Moins-Teisserenc H; Socie G
Biol Blood Marrow Transplant; 2014 Apr; 20(4):507-17. PubMed ID: 24406505
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.
Goldstein SC; Porter DL
Expert Rev Hematol; 2010 Jun; 3(3):301-14. PubMed ID: 21082981
[TBL] [Abstract][Full Text] [Related]
16. The who's who of T-cell differentiation: human memory T-cell subsets.
Mahnke YD; Brodie TM; Sallusto F; Roederer M; Lugli E
Eur J Immunol; 2013 Nov; 43(11):2797-809. PubMed ID: 24258910
[TBL] [Abstract][Full Text] [Related]
17. [NKT cell-mediated immunotherapy for hematological malignancies].
Fujii S
Rinsho Ketsueki; 2007 Mar; 48(3):188-99. PubMed ID: 17441475
[No Abstract] [Full Text] [Related]
18. Peripheral blood-derived virus-specific memory stem T cells mature to functional effector memory subsets with self-renewal potency.
Schmueck-Henneresse M; Sharaf R; Vogt K; Weist BJ; Landwehr-Kenzel S; Fuehrer H; Jurisch A; Babel N; Rooney CM; Reinke P; Volk HD
J Immunol; 2015 Jun; 194(11):5559-67. PubMed ID: 25917088
[TBL] [Abstract][Full Text] [Related]
19. Cellular adoptive immunotherapy after autologous and allogeneic hematopoietic stem cell transplantation.
Porter DL; Hexner EO; Cooley S; Miller JS
Cancer Treat Res; 2009; 144():497-537. PubMed ID: 19779876
[No Abstract] [Full Text] [Related]
20. Immunotherapeutic approaches for hematologic malignancies.
Caligiuri MA; Velardi A; Scheinberg DA; Borrello IM
Hematology Am Soc Hematol Educ Program; 2004; ():337-53. PubMed ID: 15561691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
